Abstract
Abstract
Major, spontaneous bleeding is uncommon in patients with plasma cell dyscrasias despite frequent abnormal screening hemostasis tests. However, acquired von Willebrand deficiency and light-chain (AL) amyloidosis, and amyloidosis complicating multiple myeloma can present with serious hemorrhagic complications that are challenging to manage. While patients with monoclonal gammapathy of undetermined significance and multiple myeloma share an intrinsic increased risk of venous thromboembolic events (VTE), treatment with thalidomide and lenalidomide increases the incidence of VTE in certain multiple myeloma patient subsets. Our understanding of the complex interactions among malignant plasma cells, inflammatory and hemostasis pathways, and treatment modalities that combine to produce thrombotic complications is incomplete. Prospective, randomized trials are clearly needed to assist clinicians in providing optimal VTE prophylaxis to their patients with plasma cell dyscrasias.
Publisher
American Society of Hematology
Reference67 articles.
1. Eby C, Blinder M. Hemostatic complications associated with paraproteinemias. Curr Hematol Rep. 2003;2:388–394.
2. Perkins H, MacKenzie M, Fudenberg H. Hemostatic defects in dysproteinemias. Blood. 1970;35:695–707.
3. Lackner H. Hemostatic abnormalities associated with dysproteinemias. Semin Hematol. 1973;10:125–133.
4. Kyle R, Gertz M, Witzig T, Lust J, Lacy M, Greipp P. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.
5. Kyrtsonis M, Vassilakopoulos T, Angelopuolou M, Siakantaris M, Pangalis G. Waldenstrom’s macoglobulinemia: clinical course and prognostic factors in 60 patients. Ann Hematol. 2001;80:722–727.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献